P2, N=150, Recruiting, Ann-Sofie Backman | N=260 --> 150 | Trial completion date: Oct 2038 --> Sep 2045 | Trial primary completion date: Oct 2028 --> Sep 2032

The combination of Danlou tablets and aspirin significantly improves clinical symptoms in CHD patients with phlegm and blood stasis syndrome, reduces serum sPLA2, LP-PLA2, and ox-LDL levels, and inhibits inflammatory responses, suggesting this combination could provide a beneficial adjunctive therapy for managing CHD in these patients. This study serves as a reference for further research on Danlou tablets' role in CHD.

Upon initiation of high-dose immunoglobulin therapy and aspirin, his fever subsided, and his inflammatory markers and imaging findings normalised...Importantly, IL-17A and tumour necrosis factor-α levels were normal, as elevations in these cytokines have been linked to TAK recurrence. Notably, some cases of LVV following COVID-19 do not respond well to treatment; further research, including case accumulation and cytokine profile analysis, is needed to better predict prognosis.

P2, N=88, Not yet recruiting, Virginia Commonwealth University

P1, N=34, Recruiting, Amzell

The arachidonic acid pathway inhibitor aspirin selectively inhibited the growth of ARID1A-deficient CRC, and aspirin sensitized tumors lacking ARID1A to immunotherapy. Together, these findings suggest that blocking arachidonic acid metabolism can enhance immune responses against tumors by activating CD8+ T cells and inhibiting VM, which synergizes with ICIs to improve treatment of ARID1A-deficient CRC.

P4, N=1200, Not yet recruiting, Kyoto University

P4, N=6504, Not yet recruiting, Asan Medical Center

P1, N=101, Completed, University of Melbourne | Recruiting --> Completed

P4, N=3200, Active, not recruiting, University of Vigo | Recruiting --> Active, not recruiting

P2, N=82, Terminated, Emory University | Phase classification: P1 --> P2 | Trial completion date: Oct 2024 --> Feb 2024 | Recruiting --> Terminated | Trial primary completion date: Oct 2024 --> Feb 2024; This study was terminated after interim analyses showed no benefits.

While free IND was active at a concentration of 270.5 μM, in the form of the phospholipid conjugate (IND-OA-PC), it inhibited the growth of cancer cells at 67.5 μM and after conjugate encapsulation (IND-OA-PC-NLC) it was effective at only 10.3 μM. Our study revealed that the conjugation of NSAID with phosphatidylcholine and its combination with nanotechnology techniques create opportunities to repurpose well-known drugs from this group for new therapeutic applications.

P4, N=103, Active, not recruiting, NYU Langone Health | Recruiting --> Active, not recruiting

P=N/A, N=68419, Completed, Mayo Clinic | Active, not recruiting --> Completed

P3, N=114, Completed, Swiss Group for Clinical Cancer Research | Active, not recruiting --> Completed | N=185 --> 114

P=N/A, N=432, Recruiting, Central Hospital, Nancy, France | Trial completion date: Oct 2025 --> Oct 2026

P4, N=5068, Not yet recruiting, University of Aarhus

In addition, the animals treated with IC-Sf did not present toxic effects. In conclusion, IC-Sf protected the gastrointestinal tract against the harmful effects of naproxen by inhibiting the inflammatory response and lipid peroxidation, suggesting its potential as a new therapeutic agent or food additive.

P2, N=130, Active, not recruiting, Stanford University | N=51 --> 130

P1, N=38, Not yet recruiting, Bayer | Trial completion date: Dec 2024 --> Mar 2025 | Initiation date: Nov 2024 --> Feb 2025 | Trial primary completion date: Dec 2024 --> Mar 2025

P=N/A, N=200, Enrolling by invitation, Norwegian University of Science and Technology | Not yet recruiting --> Enrolling by invitation

P=N/A, N=300, Recruiting, Cairo University

Immunohistochemistry was employed to assess the expression levels of COX-2, CD31, VEGFA, MMP2, and MMP9 in tumor tissues in order to investigate the antioxidant properties of garlic peel extract, specifically its ability to suppress COX-2 expression. The findings of this study offer a foundation for the advancement of garlic peel-based functional products and contribute to the identification of potential anti-cancer agents and therapeutic targets.

P3, N=540, Not yet recruiting, Amzell

This drug delivery system (DI/Pep1) can transport doxorubicin (DOX) and indomethacin (IND) simultaneously to target tumor cells for subsequent drug release while extending drug retention within tumor cells, which increases immunogenic cell death and facilitates the immunotherapeutic effect of CD4+ T cells. Ultimately, DI/Pep1 attenuated tumor-associated inflammation, enhanced the body's immune response, and inhibited breast cancer growth by combining the actions of DOX and IND. Our research offers an approach to hopefully enhance the effectiveness of cancer treatment.

Adjuvant treatment with VD can increase the proportion of regulatory T cells in peripheral blood of individuals with recurrent abortion, regulate metabolic disorder, alleviate immune inflammation, and improve pregnancy outcome.

Molecular docking studies revealed that selected protein targets strongly interact with bioactive compounds, and the estimated inhibition constants (Ki) of JAK2, STAT3, COX-2, HPV31 E6, EGFR1, TP53, and PARP1 were significantly decreased compared to acetylsalicylic acid. This could be a clear indication that these protein targets are implicated with antiproliferative efficacy, thereby warranting the potential of (1) and (7) to be used as anti-breast cancer drug candidates.

SANT of the spleen is generally considered a rare, benign lesion with angioma-like characteristics. It exhibits exhibiting distinctive histomorphological features within the red pulp. Understanding the differential diagnosis is crucial to prevent missed or incorrect diagnoses.

P3, N=1184, Recruiting, Capital Medical University | Not yet recruiting --> Recruiting

P=N/A, N=216, Recruiting, China-Japan Friendship Hospital | Not yet recruiting --> Recruiting

P=N/A, N=37, Completed, Carol Davila University of Medicine and Pharmacy | Recruiting --> Completed

P4, N=1050, Not yet recruiting, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University

P4, N=100, Not yet recruiting, Qingdao Traditional Chinese Medicine Hospital; Qingdao Traditional Chinese Medicine Hospital

P=N/A, N=1200, Active, not recruiting, Washington University School of Medicine | Not yet recruiting --> Active, not recruiting | N=400 --> 1200 | Trial completion date: Jun 2024 --> Nov 2024

P1/2, N=30, Recruiting, Beni-Suef University | Trial completion date: Dec 2024 --> May 2025

Thus, this pilot study suggests that the reduction in p87 in the right colon is possibly correlated with JAK3 mutations. If confirmed, JAK3 mutations, known to be associated with immune aberrations, may provide a mechanistic explanation for the lack of a p87 (protein 87 kilodaltons) field in some patients with HGD polyps who might benefit from possible intervention such as more intensive screening. Limited microbiome studies were also performed on two patients with familial cancer syndromes and these compared favorably with controls available from the literature.

P3, N=286, Recruiting, Hanmi Pharmaceutical Company Limited | Not yet recruiting --> Recruiting

P4, N=10742, Recruiting, Ohio State University | Not yet recruiting --> Recruiting

Moreover, we found that ciclopirox (CPX), an antifungal drug, induces OMA1 self-cleavage and L-OMA1 degradation in cultured OS cells. CPX also reduces tumor development of control OS cells but not OMA1-deficient OS cells in mice. These findings strongly support the important role of OMA1 in OS tumorigenesis and suggest that OMA1 may be a valuable prognostic marker and a promising therapeutic target for OS.

P1, N=24, Completed, AFT Pharmaceuticals Ltd | Recruiting --> Completed

Male Wistar rats were grouped as follows (eight rats in each): control, CFA, CFA + indomethacin (5 mg/kg), CFA + DFHE (50 mg/kg), and CFA + DFHE (100 mg/kg)...MDA and TNF-α levels were decreased while thiol levels and SOD and GPx activities were increased in DFHE-treated groups compared to the CFA group. These results suggest that D. kaki extract caused an improvement in clinical signs of rheumatoid arthritis symptoms possibly through suppression of oxidative stress and inflammation.

P3, N=400, Active, not recruiting, Weill Medical College of Cornell University | Enrolling by invitation --> Active, not recruiting | Trial completion date: Aug 2024 --> Nov 2024 | Trial primary completion date: Aug 2024 --> Nov 2024